Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.
증례보고
1/5 보강
[BACKGROUND] Due to its rarity, synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma (sdpHCC-ICC) presents significant challenges for preoperative diagnosis and is l
APA
He YC, Dai XY, et al. (2025). Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.. Frontiers in oncology, 15, 1670818. https://doi.org/10.3389/fonc.2025.1670818
MLA
He YC, et al.. "Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis.." Frontiers in oncology, vol. 15, 2025, pp. 1670818.
PMID
41211417 ↗
Abstract 한글 요약
[BACKGROUND] Due to its rarity, synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma (sdpHCC-ICC) presents significant challenges for preoperative diagnosis and is lacking established systemic therapies. Here, we present an extremely rare case of unresectable collision-type sdpHCC-ICC with pulmonary metastases, who achieved significant responses in both pulmonary metastases and hepatic lesions following combination immunotherapy.
[CASE REPORT] This case report describes a 69-year-old male diagnosed with collision-type sdpHCC-ICC accompanied by pulmonary metastases. The patient underwent combination immunotherapy with dual immune therapy of nivolumab plus ipilimumab and bevacizumab, achieving complete remission (CR) of pulmonary lesions and partial response (PR) in hepatic lesions. Subsequent surgical resection of the residual liver tumor and postoperative adjuvant therapy resulted in favorable long-term outcomes.
[CONCLUSION] Our study reports the first case that systematic therapy achieved successful conversion therapy in an unresectable sdpHCC-ICC. Combination immunotherapy might represent a promising therapeutic strategy for sdpHCC-ICC, warranting further validation.
[CASE REPORT] This case report describes a 69-year-old male diagnosed with collision-type sdpHCC-ICC accompanied by pulmonary metastases. The patient underwent combination immunotherapy with dual immune therapy of nivolumab plus ipilimumab and bevacizumab, achieving complete remission (CR) of pulmonary lesions and partial response (PR) in hepatic lesions. Subsequent surgical resection of the residual liver tumor and postoperative adjuvant therapy resulted in favorable long-term outcomes.
[CONCLUSION] Our study reports the first case that systematic therapy achieved successful conversion therapy in an unresectable sdpHCC-ICC. Combination immunotherapy might represent a promising therapeutic strategy for sdpHCC-ICC, warranting further validation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- CRISPR/Cas9 Screening Reveals that UBE2L3 Modulates Autophagic Flux through TSC2 Ubiquitination and Potentiates PD-1 Blockade in Triple-Negative Breast Cancer.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
- Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system.
- Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study.